GO:0006253 dCTP catabolic process: Nucleotide Pool Homeostasis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006253 (dCTP catabolic process) describes the chemical reactions and pathways that break down deoxycytidine triphosphate (dCTP), a key building block of DNA.
• Balanced dCTP pools are essential for faithful DNA replication and repair; imbalances are associated with mutagenesis and chemoresistance in cancer.
• The dCTP catabolic process is intimately linked to dCTP synthesis and salvage, with enzymes such as DCTPP1 and RRM1 controlling dCTP levels.
• DCTPP1 is a major dCTP pyrophosphatase that hydrolyzes dCTP and is a promising target in colorectal cancer.
• RRM1, the regulatory subunit of ribonucleotide reductase, influences dCTP pools and sensitivity to nucleoside analogs like decitabine.
• Studying dCTP catabolism requires integrated approaches including CRISPR knockout, metabolic profiling, and structural biology.
Description
The dCTP catabolic process (GO:0006253) encompasses the biochemical reactions that degrade deoxycytidine triphosphate (dCTP), a nucleotide essential for DNA synthesis and repair. Proper regulation of dCTP levels is critical because an imbalance in deoxyribonucleotide pools can lead to misincorporation of nucleotides, DNA damage, and genomic instability. This process is therefore a key node in nucleotide metabolism, with implications for cancer, antiviral therapy, and chemoresistance. Researchers study dCTP catabolism to understand how cells maintain dNTP homeostasis and to identify therapeutic targets that exploit metabolic vulnerabilities in diseases such as cancer.
dCTP catabolic process At A Glance
| GO ID | GO:0006253 |
|---|---|
| GO term | dCTP catabolic process |
| Ontology | biological_process |
| Synonym | dCTP breakdown, dCTP catabolism, dCTP degradation |
| Definition | The chemical reactions and pathways resulting in the breakdown of dCTP, deoxycytidine triphosphate. |
| Major function | Regulation of cellular dCTP levels and maintenance of deoxyribonucleotide pool balance. |
| Related processes | dCTP biosynthetic process, dNTP catabolism, pyrimidine deoxyribonucleotide metabolism. |
| Key enzymes | DCTPP1 (dCTP pyrophosphatase), RRM1 (ribonucleotide reductase subunit), and other nucleotidases. |
| Disease relevance | Cancer chemoresistance, metabolic reprogramming, and potential antiviral targets. |
What Is GO:0006253?
The dCTP catabolic process (GO:0006253) is defined as the chemical reactions and pathways resulting in the breakdown of dCTP, deoxycytidine triphosphate. This includes enzymatic hydrolysis of dCTP to dCMP and pyrophosphate, as well as subsequent dephosphorylation steps that ultimately yield deoxycytidine and inorganic phosphate. The process is part of the broader nucleotide catabolic network and is essential for balancing dCTP concentrations within the cell.
Why Is dCTP catabolic process Important in Cell Biology?
The dCTP catabolic process is crucial for maintaining the delicate balance of deoxyribonucleotide pools required for accurate DNA replication and repair. Disruption of this balance can cause mutagenesis and cell death, and is exploited in cancer therapy with nucleoside analogs such as gemcitabine and decitabine. Understanding dCTP catabolism provides insights into mechanisms of chemoresistance and identifies new targets for therapeutic intervention.
• Maintains dNTP pool homeostasis to prevent replication stress and genomic instability.
• Regulates dCTP availability for DNA synthesis and repair.
• Influences sensitivity to nucleoside analog drugs like gemcitabine and decitabine.
• DCTPP1, a key dCTP catabolic enzyme, is overexpressed in colorectal cancer and linked to metabolic reprogramming.
• RRM1 inhibition alters dCTP pools and sensitizes lung adenocarcinoma to decitabine.
• IDH2 mutations can reprogram nucleotide metabolism and contribute to chemoresistance in urothelial cancer.
• Provides potential targets for antiviral and anticancer drug development.
• Structural studies of CTP/dCTP synthases reveal mechanisms of nucleotide binding and catalysis.
• Epigenetic inheritance may be influenced by dCTP availability for DNA methylation processes.
• dCTP catabolism is part of the broader pyrimidine metabolic network that can be targeted in precision medicine.
What Happens During dCTP catabolic process?
Hydrolysis of dCTP to dCMP
In simple terms: The first step is the removal of two phosphate groups from dCTP, leaving dCMP.
The primary reaction in dCTP catabolism is the hydrolysis of dCTP to deoxycytidine monophosphate (dCMP) and pyrophosphate. This reaction is catalyzed by dCTP pyrophosphatase (DCTPP1), which specifically hydrolyzes dCTP and other deoxynucleoside triphosphates. DCTPP1 plays a critical role in regulating cellular dCTP levels and preventing incorporation of modified nucleotides into DNA.
Dephosphorylation of dCMP to deoxycytidine
In simple terms: The remaining phosphate is removed, producing deoxycytidine.
Following the formation of dCMP, further dephosphorylation by nucleotidases removes the final phosphate group, yielding deoxycytidine. This step is part of the salvage pathway and allows the nucleoside to be either excreted or re-phosphorylated for reuse. The balance between catabolism and salvage is essential for maintaining dNTP pools.
Regulation by ribonucleotide reductase
In simple terms: Ribonucleotide reductase controls the production of dCTP, indirectly affecting how much is available for breakdown.
Ribonucleotide reductase (RNR), composed of RRM1 and RRM2 subunits, catalyzes the reduction of ribonucleotides to deoxyribonucleotides, including the production of dCDP, a precursor of dCTP. The activity of RNR is tightly regulated to balance dNTP pools, and inhibition of RRM1 can alter dCTP levels and sensitize cancer cells to nucleoside analogs. Thus, dCTP catabolism is interconnected with dCTP synthesis to maintain homeostasis.
Integration with pyrimidine metabolism
In simple terms: dCTP breakdown is part of the larger pyrimidine degradation network.
The dCTP catabolic process is embedded within pyrimidine metabolism. dCTP can be deaminated to dUTP, which is then hydrolyzed to dUMP, a precursor for thymidylate synthesis. Alternatively, dCTP can be directly degraded via DCTPP1. These pathways ensure that excess dCTP is removed and that intermediates are recycled or directed to other biosynthetic routes.
Role in chemoresistance
In simple terms: Cancer cells can alter dCTP breakdown to resist chemotherapy.
Altered dCTP catabolism contributes to chemoresistance. For example, IDH2 mutations stabilize HIF-1α-induced metabolic reprogramming, which can affect nucleotide pools and promote resistance to chemotherapy in urothelial cancer. Similarly, DCTPP1 overexpression in colorectal cancer regulates metabolic reprogramming and may contribute to drug resistance. Targeting dCTP catabolic enzymes could therefore overcome chemoresistance.
Key Genes Involved in GO:0006253 dCTP catabolic process
The following genes and proteins are directly or indirectly involved in the dCTP catabolic process and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DCTPP1 | dCTP pyrophosphatase; hydrolyzes dCTP to dCMP | Target in colorectal cancer; regulates metabolic reprogramming |
| RRM1 | Regulatory subunit of ribonucleotide reductase; controls dNTP synthesis | Inhibition sensitizes lung adenocarcinoma to decitabine |
| RRM2 | Catalytic subunit of ribonucleotide reductase | Involved in dNTP pool balance; potential target in cancer |
| IDH2 | Mitochondrial isocitrate dehydrogenase; mutant forms alter metabolism | Stabilizes HIF-1α and promotes chemoresistance in urothelial cancer |
| HIF-1α | Hypoxia-inducible factor; regulates metabolic genes | Induced by IDH2 mutations; affects nucleotide metabolism |
| DNMT1 | DNA methyltransferase; maintains methylation patterns | SUMOylation by DAXX affects chromatin trapping; links to nucleotide metabolism |
| DAXX | Chromatin-associated protein; promotes SUMOylation | Regulates DNMT1 and epigenetic inheritance |
| CTP/dCTP synthase | Bifunctional enzyme synthesizing CTP and dCTP | Structural studies reveal nucleotide binding mechanisms |
| NME1 | Nucleoside diphosphate kinase; interconverts nucleotides | May influence dCTP levels; not directly cited in provided list |
| NME2 | Nucleoside diphosphate kinase; interconverts nucleotides | May influence dCTP levels; not directly cited in provided list |
| dUTPase | Hydrolyzes dUTP to dUMP; prevents uracil incorporation | Indirectly affects dCTP catabolism via pyrimidine pool |
| Thymidylate synthase | Synthesizes dTMP from dUMP | Competes with dCTP catabolism for dUMP |
| CMPK1 | UMP-CMP kinase; phosphorylates dCMP | Involved in salvage of dCMP; not directly cited in provided list |
| NT5C | 5'-nucleotidase; dephosphorylates dCMP | Participates in dCTP catabolism; not directly cited in provided list |
| SAMHD1 | dNTP triphosphohydrolase; degrades dNTPs | Regulates dNTP pools; not directly cited in provided list |
| p53 | Tumor suppressor; regulates nucleotide metabolism | Indirectly affects dCTP pools; not directly cited in provided list |
| MYC | Oncogene; drives nucleotide synthesis | Indirectly affects dCTP levels; not directly cited in provided list |
| mTOR | Kinase; regulates cell growth and metabolism | May influence nucleotide metabolism; not directly cited in provided list |
How Is dCTP catabolic process Regulated?
The dCTP catabolic process is regulated at multiple levels. Ribonucleotide reductase (RRM1/RRM2) controls the synthesis of dCDP, the precursor of dCTP, and its activity is feedback-inhibited by dNTPs. DCTPP1, the primary dCTP pyrophosphatase, is regulated by cellular demand for dNTPs and can be induced under conditions of metabolic stress. Additionally, oncogenic signaling pathways such as HIF-1α and IDH2 mutations can reprogram nucleotide metabolism, affecting dCTP catabolism and contributing to chemoresistance. The interplay between synthesis, salvage, and catabolism ensures that dCTP levels are maintained within a narrow range to support DNA replication and repair.
dCTP catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DCTPP1 | Colorectal cancer; metabolic reprogramming | HCT116 or SW480 knockout/overexpression models |
| RRM1 | Lung adenocarcinoma; chemoresistance | A549 or H1299 knockout and decitabine sensitivity assays |
| IDH2 | Urothelial cancer; chemoresistance | T24 or RT4 cells with mutant IDH2 knock-in |
| DNMT1 | Epigenetic inheritance; cancer | Knock-in of SUMOylation-deficient DNMT1 in HEK293T |
| CTP/dCTP synthase | Nucleotide metabolism; cancer | Structural studies and enzymatic assays |
Cancer Chemoresistance
Altered dCTP catabolism is implicated in resistance to nucleoside analog chemotherapies. In urothelial cancer, IDH2 mutations stabilize HIF-1α-induced metabolic reprogramming, which can increase dCTP pools and reduce drug efficacy. In colorectal cancer, DCTPP1 overexpression promotes metabolic reprogramming and is associated with poor prognosis, making it a potential therapeutic target. Similarly, RRM1 inhibition sensitizes lung adenocarcinoma to decitabine by modulating dCTP levels.
Metabolic Reprogramming in Tumors
Tumor cells often reprogram nucleotide metabolism to support rapid proliferation. DCTPP1 is a key enzyme in this reprogramming, as it regulates dCTP catabolism and maintains dNTP balance. Targeting DCTPP1 with small-molecule inhibitors has shown promise in preclinical models of colorectal cancer. This highlights the potential of targeting dCTP catabolic pathways in cancer therapy.
Epigenetic Regulation and DNA Methylation
dCTP availability can influence DNA methylation by affecting the synthesis of S-adenosylmethionine and the activity of DNA methyltransferases. DAXX promotes SUMOylation of DNMT1, which affects its chromatin trapping and epigenetic inheritance. Although direct links between dCTP catabolism and methylation are not fully established, nucleotide pool imbalances can impact epigenetic stability.
From dCTP catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DCTPP1 loss alter dCTP levels and sensitivity to nucleoside analogs? | DCTPP1 knockout in colorectal cancer cell lines (e.g., HCT116) |
| Does mutant IDH2 affect dCTP catabolism and chemoresistance? | IDH2 R172K knock-in in urothelial cancer cells |
| Does RRM1 inhibition sensitize to decitabine? | RRM1 knockout or knockdown in lung adenocarcinoma cells |
| How does DAXX-mediated SUMOylation of DNMT1 affect epigenetic inheritance? | DAXX knockout or SUMOylation-site mutant knock-in |
| What is the structural basis of dCTP binding to CTP/dCTP synthase? | Recombinant protein expression and X-ray crystallography |
| Can small-molecule inhibitors of DCTPP1 suppress tumor growth? | Patient-derived xenografts or organoids with DCTPP1 overexpression |
How to Study the dCTP catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Intracellular dCTP and dNTP concentrations | Assessing changes after gene knockout or drug treatment |
| CRISPR-Cas9 knockout | Gene function by loss-of-function | Validating DCTPP1 or RRM1 as therapeutic targets |
| X-ray crystallography | Three-dimensional protein structure | Understanding dCTP binding and catalysis |
| Enzymatic activity assay | Hydrolysis of dCTP to dCMP | Screening for DCTPP1 inhibitors |
| RNA-seq | Transcriptional changes in nucleotide metabolism genes | Identifying compensatory pathways |
| Western blot | Protein expression levels | Confirming knockout or overexpression |
| Cell viability assay | Drug sensitivity | Testing chemoresistance in knockout models |
| Flow cytometry | Cell cycle and apoptosis | Evaluating effects of dCTP pool imbalance |
Metabolic Profiling by LC-MS
Liquid chromatography-mass spectrometry (LC-MS) is used to quantify dCTP and other nucleotides in cell extracts. This method allows researchers to measure changes in dCTP pools upon genetic manipulation or drug treatment.
CRISPR-Cas9 Knockout Screens
Genome-wide CRISPR knockout screens can identify genes that regulate dCTP catabolism and sensitivity to nucleoside analogs. For example, knockout of DCTPP1 or RRM1 can be validated in cancer cell lines to assess effects on dCTP levels and drug response.
Structural Biology
X-ray crystallography and cryo-EM provide insights into the catalytic mechanisms of enzymes involved in dCTP catabolism, such as DCTPP1 and CTP/dCTP synthase. Structural studies guide the design of inhibitors targeting these enzymes.
Enzymatic Assays
In vitro enzymatic assays using recombinant proteins measure the hydrolysis of dCTP to dCMP and pyrophosphate. These assays are used to characterize enzyme kinetics and screen for inhibitors.
How CRISPR Can Be Used to Study GO:0006253 dCTP catabolic process
Knockout
CRISPR-Cas9 knockout of DCTPP1 or RRM1 can be used to study their roles in dCTP catabolism. Knockout cells exhibit altered dCTP levels and changed sensitivity to nucleoside analogs, providing causal evidence for their function.
Point Mutation
Point mutations in the catalytic site of DCTPP1 or in the RRM1 subunit can be introduced to dissect enzymatic mechanisms. For example, mutation of the catalytic cysteine in DCTPP1 abolishes its pyrophosphatase activity, allowing researchers to separate catalytic from non-catalytic functions.
Knock-in
Knock-in of mutant IDH2 (e.g., R172K) in urothelial cancer cells can model the metabolic reprogramming observed in patients. This approach helps to establish how mutant IDH2 affects dCTP catabolism and chemoresistance.
Overexpression
Overexpression of DCTPP1 or RRM1 in cancer cell lines can mimic the elevated levels seen in tumors. Such models are useful for testing the efficacy of targeted inhibitors and understanding the contribution of these enzymes to drug resistance.
How EDITGENE Supports dCTP catabolic process Research
Researchers studying dCTP catabolic process-related genes often need to determine whether a candidate gene is causally involved in nucleotide pool regulation, chemoresistance, or metabolic reprogramming. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional validation in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for dCTP catabolic process research.
Frequently Asked Questions About dCTP catabolic process
What is dCTP catabolic process?
The dCTP catabolic process (GO:0006253) is the set of biochemical reactions that break down deoxycytidine triphosphate (dCTP) into smaller molecules, such as dCMP and deoxycytidine, helping to regulate cellular dCTP levels.
What genes are involved in dCTP catabolic process?
Key genes include DCTPP1 (dCTP pyrophosphatase), RRM1 (ribonucleotide reductase subunit), and IDH2, which can influence dCTP pools and catabolism.
Why is dCTP catabolism important in cancer?
Altered dCTP catabolism can lead to chemoresistance by changing dCTP pools and affecting the efficacy of nucleoside analog drugs like gemcitabine and decitabine.
How is dCTP catabolic process regulated?
It is regulated by enzymes such as DCTPP1 and ribonucleotide reductase, which control the balance between dCTP synthesis and degradation in response to cellular needs.
What diseases are associated with dCTP catabolic process?
Dysregulation of dCTP catabolism is linked to cancer chemoresistance, metabolic reprogramming in tumors, and potentially epigenetic changes.
What methods are used to study dCTP catabolic process?
Common methods include LC-MS metabolomics, CRISPR knockout screens, enzymatic assays, and structural biology techniques like X-ray crystallography.
Can CRISPR be used to study dCTP catabolism?
Yes, CRISPR-Cas9 knockout, point mutation, and knock-in models are powerful tools to dissect the roles of genes like DCTPP1 and RRM1 in dCTP catabolism.
What is the role of DCTPP1 in dCTP catabolism?
DCTPP1 is a dCTP pyrophosphatase that hydrolyzes dCTP to dCMP, thereby regulating dCTP levels and influencing cancer cell metabolism.
How does RRM1 affect dCTP levels?
RRM1 is a subunit of ribonucleotide reductase, which synthesizes deoxyribonucleotides; its inhibition can alter dCTP pools and sensitize cancer cells to decitabine.
What are potential therapeutic targets in dCTP catabolism?
DCTPP1 and RRM1 are promising targets; inhibitors of DCTPP1 and RRM1 are being explored to overcome chemoresistance in cancers.
Conclusion
The dCTP catabolic process (GO:0006253) is a critical component of nucleotide metabolism that maintains dCTP homeostasis and influences DNA replication, repair, and chemoresistance. Key enzymes such as DCTPP1 and RRM1 are emerging as therapeutic targets in cancer, and ongoing research continues to unravel the complex regulation of this pathway. Understanding dCTP catabolism provides opportunities for developing novel strategies to overcome drug resistance and improve cancer treatment.
References
- 1. Shigeta K et al.. 2023. IDH2 stabilizes HIF-1α-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer.. EMBO J 42(4):e110620 PMID: 36637036
- 2. Feng L et al.. 2024. Identification of Novel Target DCTPP1 for Colorectal Cancer Therapy with the Natural Small-Molecule Inhibitors Regulating Metabolic Reprogramming.. Angew Chem Int Ed Engl 63(47):e202402543 PMID: 39143504
- 3. Tanimoto S et al.. 2026. DAXX promotes SUMOylation of chromatin-trapped DNMT1.. J Biochem 179(5):363-373 PMID: 41679964
- 4. Guo CJ et al.. 2024. Structural Basis of Bifunctional CTP/dCTP Synthase.. J Mol Biol 436(20):168750 PMID: 39173734
- 5. Jiang N et al.. 2026. RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment.. Cell Death Dis 17(1) PMID: 41748545
- 6. Reichard P. 1985. Ribonucleotide reductase and deoxyribonucleotide pools.. Basic Life Sci 31:33-45 PMID: 3888178
- 7. Plunkett W et al.. 1995. Preclinical characteristics of gemcitabine.. Anticancer Drugs 6 Suppl 6:7-13 PMID: 8718419
- 8. Holliday R et al.. 2002. DNA methylation and epigenetic inheritance.. Methods 27(2):179-83 PMID: 12095278
